Preferred Label : Pemziviptadil;
NCIt definition : A recombinant fusion protein composed of an analogue of the immunoregulatory neuropeptide
vasoactive intestinal peptide (VIP) and elastin-like polypeptide (ELP) biopolymer,
with potential vasodilating, anti-inflammatory, and anti-fibrotic activities. Upon
administration, pemziviptadil targets, binds to and activates VIP receptor-2 (VPAC2).
This dilates blood vessels and lowers blood pressure. Pemziviptadil may also inhibit
the production of certain pro-inflammatory mediators, such as tumor necrosis factor-alpha
(TNFa), interferon-gamma (IFN-g), interleukin-6 (IL-6) and IL-12, and may protect
the lungs against a cytokine storm and inflammation. As cytokines cause the air sacs
of the lungs to fill with water, making the sacs impermeable to oxygen, pemziviptadil
may protect against pulmonary edema, and restores the barrier function at the endothelial/alveolar
interface. This may improve blood oxygenation, respiratory distress, and prevent lung
injury. The fusion of VIP analogue to ELP allows the sustained release of the agent.
Endogenous VIP binds to both VIP receptor-1 (VPAC1) in the gastrointestinal (GI) tract
and VPAC2 in the cardiopulmonary system. The selective binding of pemziviptadil to
VPAC2 may reduce GI side effects.;
UNII : 200AW54D93;
CAS number : 1265655-87-5;
Drug name : Vasomera;
Molecule name : PB-1046; PB 1046;
NCI Metathesaurus CUI : CL1648389;
Origin ID : C179114;
UMLS CUI : C5555478;
Semantic type(s)
- concept_is_in_subset
